US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
US5807715A
(en)
|
1984-08-27 |
1998-09-15 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
|
EP0307434B2
(fr)
|
1987-03-18 |
1998-07-29 |
Scotgen Biopharmaceuticals, Inc. |
Anticorps alteres
|
WO1991003493A1
(fr)
|
1989-08-29 |
1991-03-21 |
The University Of Southampton |
CONJUGUES F(ab)3 ou F(ab)4 bi ou trispécifiques
|
EP0519596B1
(fr)
|
1991-05-17 |
2005-02-23 |
Merck & Co. Inc. |
Procédé pour réduire l'immunogénicité des domaines variables d'anticorps
|
GB9112536D0
(en)
|
1991-06-11 |
1991-07-31 |
Celltech Ltd |
Chemical compounds
|
EP1400536A1
(fr)
|
1991-06-14 |
2004-03-24 |
Genentech Inc. |
Procédé pour fabriquer des anticorps humanisés
|
WO1994004679A1
(fr)
|
1991-06-14 |
1994-03-03 |
Genentech, Inc. |
Procede pour fabriquer des anticorps humanises
|
GB9115364D0
(en)
|
1991-07-16 |
1991-08-28 |
Wellcome Found |
Antibody
|
US5843749A
(en)
|
1991-07-26 |
1998-12-01 |
Regeneron Pharmaceuticals, Inc. |
Ehk and Ror tyrosine kinases
|
CA2078539C
(fr)
|
1991-09-18 |
2005-08-02 |
Kenya Shitara |
Procede de fabrication de chimere d'anticorps humain
|
GB9225453D0
(en)
|
1992-12-04 |
1993-01-27 |
Medical Res Council |
Binding proteins
|
US6180377B1
(en)
|
1993-06-16 |
2001-01-30 |
Celltech Therapeutics Limited |
Humanized antibodies
|
US5922845A
(en)
|
1996-07-11 |
1999-07-13 |
Medarex, Inc. |
Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
|
WO1998023289A1
(fr)
|
1996-11-27 |
1998-06-04 |
The General Hospital Corporation |
Modulation de la fixation de l'igg au fcrn
|
EP0846571B1
(fr)
|
1996-12-04 |
2001-04-11 |
Agfa-Gevaert N.V. |
Procédé pour la formation d'une image améliorée par voie thermique
|
US6277375B1
(en)
|
1997-03-03 |
2001-08-21 |
Board Of Regents, The University Of Texas System |
Immunoglobulin-like domains with increased half-lives
|
CN1224712C
(zh)
|
1997-06-04 |
2005-10-26 |
牛津生物医学(英国)有限公司 |
载体
|
NZ507381A
(en)
|
1998-04-21 |
2003-12-19 |
Micromet Ag |
CD19xCD3 specific polypeptides and uses thereof
|
US7244826B1
(en)
|
1998-04-24 |
2007-07-17 |
The Regents Of The University Of California |
Internalizing ERB2 antibodies
|
AU784045B2
(en)
|
1999-06-25 |
2006-01-19 |
Genentech Inc. |
Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
|
US7192698B1
(en)
|
1999-08-17 |
2007-03-20 |
Purdue Research Foundation |
EphA2 as a diagnostic target for metastatic cancer
|
JP2003523178A
(ja)
|
1999-11-15 |
2003-08-05 |
ユニバーシティ・オブ・サザン・カリフォルニア |
治療又は診断のための成分の攻撃目標を設定したデリバリー
|
US6803192B1
(en)
|
1999-11-30 |
2004-10-12 |
Mayo Foundation For Medical Education And Research |
B7-H1, a novel immunoregulatory molecule
|
WO2001039722A2
(fr)
|
1999-11-30 |
2001-06-07 |
Mayo Foundation For Medical Education And Research |
Nouvelle molecule immunoregulatrice b7-h1,
|
CA2399832C
(fr)
|
2000-02-11 |
2011-09-20 |
Stephen D. Gillies |
Amelioration de la demi-vie circulante de proteines de fusion a base d'anticorps
|
CA2410551A1
(fr)
|
2000-06-30 |
2002-01-10 |
Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw (Vib) |
Proteines de fusion heterodimeres
|
AU9373501A
(en)
|
2000-08-14 |
2002-02-25 |
Akzo Nobel Nv |
Use of antibodies against specific mhc-peptide complexes
|
US7101976B1
(en)
|
2000-09-12 |
2006-09-05 |
Purdue Research Foundation |
EphA2 monoclonal antibodies and methods of making and using same
|
US7737258B2
(en)
|
2000-10-18 |
2010-06-15 |
Sloan-Kettering Institute For Cancer Research |
Uses of monoclonal antibody 8H9
|
US7666424B2
(en)
|
2001-10-17 |
2010-02-23 |
Sloan-Kettering Institute For Cancer Research |
Methods of preparing and using single chain anti-tumor antibodies
|
US8414892B2
(en)
|
2000-10-18 |
2013-04-09 |
Sloan-Kettering Institute For Cancer Research |
Uses of monoclonal antibody 8H9
|
US8501471B2
(en)
|
2000-10-18 |
2013-08-06 |
Sloan-Kettering Institute For Cancer Research |
Uses of monoclonal antibody 8H9
|
US7740845B2
(en)
|
2000-10-18 |
2010-06-22 |
Sloan-Kettering Institute For Cancer Research |
Uses of monoclonal antibody 8H9
|
CA2427858A1
(fr)
*
|
2000-11-03 |
2002-05-10 |
University Of Vermont And State Agricultural College |
Methodes et compositions destinees a inhiber grb7
|
ES2649037T3
(es)
|
2000-12-12 |
2018-01-09 |
Medimmune, Llc |
Moléculas con semividas prolongadas, composiciones y usos de las mismas
|
US7794710B2
(en)
|
2001-04-20 |
2010-09-14 |
Mayo Foundation For Medical Education And Research |
Methods of enhancing T cell responsiveness
|
US6833441B2
(en)
|
2001-08-01 |
2004-12-21 |
Abmaxis, Inc. |
Compositions and methods for generating chimeric heteromultimers
|
ES2276735T3
(es)
|
2001-09-14 |
2007-07-01 |
Affimed Therapeutics Ag |
Anticuerpos fv multimericos de cadena sencilla en tandem.
|
AU2002327704A1
(en)
|
2001-09-21 |
2003-04-01 |
Raven Biotechnologies, Inc. |
Antibodies that bind to cancer-associated antigen cytokeratin 8 and methods of use thereof
|
ES2328025T3
(es)
|
2001-10-09 |
2009-11-06 |
Mayo Foundation For Medical Education And Research |
Mejoramiento de las respuestas inmunitarias por anticuerpos agonistas 4-1 bb.
|
ATE524196T1
(de)
|
2001-10-16 |
2011-09-15 |
Macrogenics West Inc |
An das krebsassoziierte antigen cd46 bindende antikörper und verwendungsverfahren dafür
|
US20040048312A1
(en)
|
2002-04-12 |
2004-03-11 |
Ronghao Li |
Antibodies that bind to integrin alpha-v-beta-6 and methods of use thereof
|
US20030223989A1
(en)
|
2002-04-18 |
2003-12-04 |
Pluenneke John D. |
CD137 agonists to treat patients with IgE-mediated conditions
|
AU2003225294A1
(en)
|
2002-05-03 |
2003-11-17 |
Raven Biotechnologies, Inc. |
Alcam and alcam modulators
|
WO2003094859A2
(fr)
|
2002-05-10 |
2003-11-20 |
Medimmune, Inc. |
Anticorps monoclonaux contre epha2 et leurs méthodes d'utilisation
|
CA2490399C
(fr)
|
2002-06-19 |
2015-10-06 |
Raven Biotechnologies, Inc. |
Cible de surface cellulaire raag10 et famille d'anticorps reconnaissant cette cible
|
US8044180B2
(en)
|
2002-08-14 |
2011-10-25 |
Macrogenics, Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
US8187593B2
(en)
|
2002-08-14 |
2012-05-29 |
Macrogenics, Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
US8530627B2
(en)
|
2002-08-14 |
2013-09-10 |
Macrogenics, Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
US8946387B2
(en)
|
2002-08-14 |
2015-02-03 |
Macrogenics, Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
US8968730B2
(en)
|
2002-08-14 |
2015-03-03 |
Macrogenics Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
US8193318B2
(en)
|
2002-08-14 |
2012-06-05 |
Macrogenics, Inc. |
FcγRIIB specific antibodies and methods of use thereof
|
US7217797B2
(en)
|
2002-10-15 |
2007-05-15 |
Pdl Biopharma, Inc. |
Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
|
CA2505633A1
(fr)
|
2002-11-13 |
2004-05-27 |
Raven Biotechnologies, Inc. |
Antigene pipa et anticorps de liaison a celui-ci
|
AU2003290059A1
(en)
|
2002-12-16 |
2004-07-09 |
Herbert Schwarz |
Use of cd137 antagonists for the treatment of tumors
|
WO2004056875A1
(fr)
|
2002-12-23 |
2004-07-08 |
Wyeth |
Anticorps anti pd-1 et utilisations
|
KR100500283B1
(ko)
*
|
2003-03-25 |
2005-07-11 |
이뮤노믹스 주식회사 |
인간 4-1비비 분자에 대한 인간화 모노클로날 폴리펩티드 및 이를 포함하는 약학 조성물
|
EP1664082B1
(fr)
|
2003-09-18 |
2014-03-05 |
MacroGenics West, Inc. |
Kid3 et anticorps dirigés contre kid3
|
US7288638B2
(en)
|
2003-10-10 |
2007-10-30 |
Bristol-Myers Squibb Company |
Fully human antibodies against human 4-1BB
|
AU2004290070A1
(en)
|
2003-11-12 |
2005-05-26 |
Biogen Idec Ma Inc. |
Neonatal Fc receptor (FcRn)-binding polypeptide variants, dimeric Fc binding proteins and methods related thereto
|
CA2550551C
(fr)
|
2004-01-16 |
2013-10-29 |
Regeneron Pharmaceuticals, Inc. |
Polypeptides hybrides capables d'activer des recepteurs
|
KR101297146B1
(ko)
|
2004-05-10 |
2013-08-21 |
마크로제닉스, 인크. |
인간화 FcγRIIB 특이적 항체 및 그의 사용 방법
|
EP1765868B1
(fr)
|
2004-06-07 |
2016-04-20 |
MacroGenics, Inc. |
Anticorps contre le récepteur de transferrine
|
EP1828946B1
(fr)
|
2004-10-15 |
2018-02-28 |
Symantec International |
Mot de passe a usage unique
|
US8802820B2
(en)
|
2004-11-12 |
2014-08-12 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
US8367805B2
(en)
|
2004-11-12 |
2013-02-05 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
EP1846767B1
(fr)
|
2005-01-12 |
2012-06-06 |
MacroGenics West, Inc. |
Antigène kid31 (carboxypeptidase m) et anticorps de liaison à celui-ci
|
EP1846032A4
(fr)
|
2005-01-31 |
2009-01-28 |
Raven Biotechnologies Inc |
Luca2 et anticorps s'y liant
|
WO2006084078A2
(fr)
|
2005-02-02 |
2006-08-10 |
Raven Biotechnologies, Inc. |
Antigene jam-3 et anticorps se liant a celui-ci
|
EP1841794B1
(fr)
|
2005-02-02 |
2013-11-20 |
MacroGenics West, Inc. |
Modulateurs adam-9
|
US7572896B2
(en)
|
2005-02-03 |
2009-08-11 |
Raven Biotechnologies, Inc. |
Antibodies to oncostatin M receptor
|
US7569672B2
(en)
|
2005-02-04 |
2009-08-04 |
Raven Biotechnologies, Inc. |
Antibodies that bind to EphA2 and methods of use thereof
|
US20080019905A9
(en)
|
2005-02-18 |
2008-01-24 |
Strome Scott E |
Method of using an anti-CD137 antibody as an agent for radioimmunotherapy or radioimmunodetection
|
US20060182744A1
(en)
|
2005-02-15 |
2006-08-17 |
Strome Scott E |
Anti-CD137 antibody as an agent in the treatment of cancer and glycosylation variants thereof
|
AU2006232310B9
(en)
|
2005-04-06 |
2011-07-21 |
Ibc Pharmaceuticals, Inc. |
Improved stably tethered structures of defined compositions with multiple functions or binding specificities
|
CA2604032C
(fr)
|
2005-04-06 |
2017-08-22 |
Ibc Pharmaceuticals, Inc. |
Methodes de generation de complexes lies stablement composes d'homodimeres, d'homotetrameres ou de dimeres de dimeres et utilisations associees
|
EP3479844B1
(fr)
|
2005-04-15 |
2023-11-22 |
MacroGenics, Inc. |
Dianticorps covalents et leurs utilisations
|
US9284375B2
(en)
|
2005-04-15 |
2016-03-15 |
Macrogenics, Inc. |
Covalent diabodies and uses thereof
|
US9963510B2
(en)
|
2005-04-15 |
2018-05-08 |
Macrogenics, Inc. |
Covalent diabodies and uses thereof
|
EP3530736A3
(fr)
|
2005-05-09 |
2019-11-06 |
ONO Pharmaceutical Co., Ltd. |
Anticorps monoclonaux humains pour mort programmée 1 (pd-1) et procédés de traitement du cancer à l'aide d'anticorps anti-pd-1 seuls ou combinés à d'autres formulations immunothérapeutiques
|
SI1907424T1
(sl)
|
2005-07-01 |
2015-12-31 |
E. R. Squibb & Sons, L.L.C. |
Humana monoklonska protitelesa proti programiranem smrtnem ligandu 1 (PD-L1)
|
US7612181B2
(en)
|
2005-08-19 |
2009-11-03 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
SG2014010029A
(en)
|
2005-08-19 |
2014-08-28 |
Abbott Lab |
Dual variable domain immunoglobin and uses thereof
|
CA2607056C
(fr)
|
2005-10-19 |
2015-11-24 |
Ibc Pharmaceuticals, Inc. |
Procedes et compositions permettant de produire des ensembles bioactifs de complexite augmentee et utilisations
|
AU2006330051B2
(en)
|
2005-12-16 |
2011-08-18 |
Ibc Pharmaceuticals, Inc. |
Multivalent immunoglobulin-based bioactive assemblies
|
AU2007226696C1
(en)
|
2006-03-10 |
2016-02-04 |
Wyeth Llc |
Anti-5T4 antibodies and uses thereof
|
NZ573646A
(en)
|
2006-06-12 |
2012-04-27 |
Wyeth Llc |
Single-chain multivalent binding proteins with effector function
|
EP2032159B1
(fr)
|
2006-06-26 |
2015-01-07 |
MacroGenics, Inc. |
Combinaison d'anticorps de fc riib et d'anticorps spécifiques de cd20 et leurs procédés d'utilisation
|
AT503889B1
(de)
|
2006-07-05 |
2011-12-15 |
Star Biotechnologische Forschungs Und Entwicklungsges M B H F |
Multivalente immunglobuline
|
AT503902B1
(de)
|
2006-07-05 |
2008-06-15 |
F Star Biotech Forsch & Entw |
Verfahren zur manipulation von immunglobulinen
|
CN101522717A
(zh)
|
2006-08-04 |
2009-09-02 |
阿斯利康(瑞典)有限公司 |
针对ErbB2的人抗体
|
WO2008027236A2
(fr)
|
2006-08-30 |
2008-03-06 |
Genentech, Inc. |
Anticorps multispécifiques
|
CN101687021B
(zh)
|
2007-03-22 |
2013-04-17 |
斯隆-凯特琳癌症研究院 |
单克隆抗体8h9的应用
|
AU2008266951B2
(en)
|
2007-06-18 |
2013-12-12 |
Merck Sharp & Dohme B.V. |
Antibodies to human programmed death receptor PD-1
|
CN101821288A
(zh)
|
2007-06-21 |
2010-09-01 |
宏观基因有限公司 |
共价双抗体及其用途
|
WO2009018386A1
(fr)
|
2007-07-31 |
2009-02-05 |
Medimmune, Llc |
Protéines de liaison à épitope multispécifiques et leurs utilisations
|
US7771720B2
(en)
|
2007-09-07 |
2010-08-10 |
Cisthera, Inc. |
Humanized PAI-1 antibodies
|
WO2009117030A2
(fr)
|
2007-12-19 |
2009-09-24 |
Macrogenics, Inc. |
Compositions améliorées pour la prévention et le traitement de la variole
|
PL2247304T3
(pl)
|
2008-04-02 |
2017-01-31 |
Macrogenics, Inc. |
Przeciwciała specyficzne wobec HER2/neu oraz sposoby ich zastosowania
|
CN106349390B
(zh)
|
2008-04-02 |
2019-12-10 |
宏观基因有限公司 |
Bcr-复合体-特异性抗体和其使用方法
|
EP2113255A1
(fr)
|
2008-05-02 |
2009-11-04 |
f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. |
Immunoglobuline cytotoxique
|
WO2010033279A2
(fr)
|
2008-06-04 |
2010-03-25 |
Macrogenics, Inc. |
<sb>anticorps à liaison alteree à fcrn et leurs procedes d'utilisation</sb>
|
RS54233B1
(en)
|
2008-08-25 |
2015-12-31 |
Amplimmune Inc. |
PD-1 ANTAGONIST COMPOSITIONS AND PROCEDURES FOR THEIR APPLICATION
|
JP2012501178A
(ja)
|
2008-08-26 |
2012-01-19 |
マクロジェニクス,インコーポレーテッド |
T細胞受容体抗体およびその使用方法
|
WO2010028796A1
(fr)
|
2008-09-10 |
2010-03-18 |
F. Hoffmann-La Roche Ag |
Anticorps hexavalents trispécifiques
|
WO2010028795A1
(fr)
|
2008-09-10 |
2010-03-18 |
F. Hoffmann-La Roche Ag |
Anticorps multivalents
|
WO2010028797A1
(fr)
|
2008-09-10 |
2010-03-18 |
F. Hoffmann-La Roche Ag |
Anticorps multivalents
|
DK2342226T3
(en)
|
2008-09-26 |
2016-09-26 |
Dana Farber Cancer Inst Inc |
HUMAN ANTI-PD-1, PD-L1 AND PD-L2 ANTIBODIES AND APPLICATIONS THEREOF
|
CN106432503B
(zh)
|
2008-12-19 |
2020-03-06 |
宏观基因有限公司 |
共价双抗体及其用途
|
TWI461211B
(zh)
|
2009-03-20 |
2014-11-21 |
Genentech Inc |
抗-her抗體
|
JP2010249130A
(ja)
|
2009-03-27 |
2010-11-04 |
Sanden Corp |
流体機械
|
SG176219A1
(en)
|
2009-05-27 |
2011-12-29 |
Hoffmann La Roche |
Tri- or tetraspecific antibodies
|
DE102009040716B4
(de)
|
2009-09-10 |
2011-07-14 |
Miltenyi Biotec GmbH, 51429 |
Verwendung von CD154 zur Identifizierung und Abtrennung von nicht-regulatorischen T-Zellen aus einem Gemisch mit regulatorischen T-Zellen
|
CN102482701B
(zh)
|
2009-09-16 |
2015-05-13 |
免疫医疗公司 |
I类抗-cea抗体及其使用
|
EP3279215B1
(fr)
|
2009-11-24 |
2020-02-12 |
MedImmune Limited |
Agents de liaison ciblés contre b7-h1
|
SG10201501784YA
(en)
|
2009-12-07 |
2015-05-28 |
Univ Leland Stanford Junior |
Methods for enhancing anti-tumor antibody therapy
|
GB201000467D0
(en)
|
2010-01-12 |
2010-02-24 |
Ucb Pharma Sa |
Antibodies
|
US8802091B2
(en)
|
2010-03-04 |
2014-08-12 |
Macrogenics, Inc. |
Antibodies reactive with B7-H3 and uses thereof
|
NZ602161A
(en)
|
2010-03-04 |
2014-12-24 |
Macrogenics Inc |
Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
|
US8876892B2
(en)
|
2010-04-21 |
2014-11-04 |
Medtronic, Inc. |
Prosthetic heart valve delivery system with spacing
|
TWI586806B
(zh)
|
2010-04-23 |
2017-06-11 |
建南德克公司 |
異多聚體蛋白質之製造
|
CN103153339B
(zh)
|
2010-05-27 |
2021-05-04 |
根马布股份公司 |
针对her2表位的单克隆抗体
|
CA3051311A1
(fr)
|
2010-05-27 |
2011-12-01 |
Genmab A/S |
Anticorps monoclonaux contre her2
|
EP3327035A1
(fr)
|
2010-06-22 |
2018-05-30 |
Precision Biologics Inc. |
Antigènes et anticorps spécifiques des cancers du côlon et du pancréas
|
EP2596114A4
(fr)
|
2010-07-14 |
2014-01-08 |
Amgen Inc |
Immunoglobuline à insertion de domaine
|
JP5964300B2
(ja)
|
2010-08-02 |
2016-08-03 |
マクロジェニクス,インコーポレーテッド |
共有結合型ダイアボディおよびその使用
|
RU2710717C2
(ru)
|
2010-09-09 |
2020-01-10 |
Пфайзер Инк. |
Молекулы, связывающиеся с 4-1ВВ
|
LT2691112T
(lt)
|
2011-03-31 |
2018-07-25 |
Merck Sharp & Dohme Corp. |
Stabilios antikūnų kompozicijos prieš žmogaus programuojamos mirties receptorių pd-1 ir susiję gydymo būdai
|
LT2699264T
(lt)
|
2011-04-20 |
2018-07-10 |
Medimmune, Llc |
Antikūnai ir kitos molekulės, kurios jungiasi prie b7-h1 ir pd-1
|
DK2703486T3
(en)
|
2011-04-25 |
2018-05-28 |
Daiichi Sankyo Co Ltd |
ANTI-B7-H3 ANTIBODY
|
ES2703780T3
(es)
|
2011-05-17 |
2019-03-12 |
Trion Res Gmbh |
Preparación de una vacuna que contiene anticuerpos trifuncionales con propiedades potenciadoras de la inmunogenicidad del antígeno
|
KR20190105112A
(ko)
|
2011-05-21 |
2019-09-11 |
마크로제닉스, 인크. |
사람 및 비-사람 cd3에 결합할 수 있는 cd3-결합 분자
|
NZ618016A
(en)
|
2011-05-21 |
2015-05-29 |
Macrogenics Inc |
Deimmunized serum-binding domains and their use for extending serum half-life
|
WO2012162583A1
(fr)
|
2011-05-26 |
2012-11-29 |
Ibc Pharmaceuticals, Inc. |
Conception et construction de nouveaux anticorps multivalents
|
US20150045540A1
(en)
|
2011-06-28 |
2015-02-12 |
Sea Lane Biotechnologies, Llc |
Multispecific stacked variable domain binding proteins
|
WO2013006544A1
(fr)
|
2011-07-06 |
2013-01-10 |
Medimmune, Llc |
Procédé de préparation de polypeptides multimères
|
WO2013014668A1
(fr)
|
2011-07-24 |
2013-01-31 |
Curetech Ltd. |
Variants d'anticorps monoclonaux immunomodulateurs humanisés
|
KR101723273B1
(ko)
|
2011-08-23 |
2017-04-04 |
로슈 글리카트 아게 |
2 개의 fab 단편을 포함하는 fc-부재 항체 및 이용 방법
|
US20130071403A1
(en)
|
2011-09-20 |
2013-03-21 |
Vical Incorporated |
Synergistic anti-tumor efficacy using alloantigen combination immunotherapy
|
CA2846432A1
(fr)
|
2011-09-23 |
2013-03-28 |
Amgen Research (Munich) Gmbh |
Molecules de liaison bispecifiques pour 5t4 et cd3
|
CA2851795C
(fr)
|
2011-10-20 |
2018-11-13 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Recepteurs d'antigenes chimeriques anti-cd22
|
EP2776061B1
(fr)
|
2011-11-07 |
2019-08-14 |
MedImmune, LLC |
Protéines de liaison multispécifiques et multivalentes et leurs utilisations
|
KR101981873B1
(ko)
|
2011-11-28 |
2019-05-23 |
메르크 파텐트 게엠베하 |
항-pd-l1 항체 및 그의 용도
|
CA2863944A1
(fr)
|
2012-02-10 |
2013-08-15 |
Research Corporation Technologies, Inc. |
Proteines de fusion comprenant des chaines principales issues du domaine constant des immunoglobulines
|
BR112014025830A8
(pt)
|
2012-04-20 |
2017-10-10 |
Emergent Product Dev Seattle |
Polipeptídeos de ligação ao cd3
|
WO2013163427A1
(fr)
|
2012-04-25 |
2013-10-31 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Anticorps pour traiter les infections par le vih-1
|
KR20150013188A
(ko)
|
2012-05-24 |
2015-02-04 |
에프. 호프만-라 로슈 아게 |
다중특이적 항체
|
WO2014022540A1
(fr)
|
2012-08-02 |
2014-02-06 |
Regeneron Pharmaceuticals, Inc. |
Protéines multivalentes de liaison à un antigène
|
CN111499755A
(zh)
|
2012-08-03 |
2020-08-07 |
丹娜法伯癌症研究院 |
抗-pd-l1和pd-l2双结合抗体单一试剂及其使用方法
|
JOP20200236A1
(ar)
|
2012-09-21 |
2017-06-16 |
Regeneron Pharma |
الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
|
BR112015007672A2
(pt)
|
2012-10-04 |
2017-08-08 |
Dana Farber Cancer Inst Inc |
anticorpos anti-pd-l1 monoclonais humanos e métodos de uso
|
EP2943511B1
(fr)
|
2013-01-14 |
2019-08-07 |
Xencor, Inc. |
Nouvelles protéines hétérodimères
|
MX2015010843A
(es)
|
2013-02-26 |
2016-04-04 |
Roche Glycart Ag |
Moleculas biespecificas de union al antigeno que activan celulas t.
|
WO2014137931A1
(fr)
|
2013-03-06 |
2014-09-12 |
Imaginab, Inc. |
Constructions de liaison à un antigène se liant à 5t4
|
MX2015012709A
(es)
|
2013-03-14 |
2016-05-31 |
Macrogenics Inc |
Moleculas biespecificas que son inmunorreactivas con celulas efectoras inmunes que expresan un receptor activador y un antigeno expresado por una celula infectada por un virus y usos de las mismas.
|
AU2014259719B2
(en)
|
2013-05-02 |
2019-10-03 |
Anaptysbio, Inc. |
Antibodies directed against programmed death-1 (PD-1)
|
KR101453462B1
(ko)
*
|
2013-05-16 |
2014-10-23 |
앱클론(주) |
Her2에 특이적으로 결합하는 항체
|
CA2913977C
(fr)
|
2013-05-31 |
2022-11-29 |
Sorrento Therapeutics, Inc. |
Proteines de liaison a l'antigene qui se lient a pd-1
|
UA116479C2
(uk)
|
2013-08-09 |
2018-03-26 |
Макродженікс, Інк. |
БІСПЕЦИФІЧНЕ МОНОВАЛЕНТНЕ Fc-ДІАТІЛО, ЯКЕ ОДНОЧАСНО ЗВ'ЯЗУЄ CD32B I CD79b, ТА ЙОГО ЗАСТОСУВАННЯ
|
EP2839842A1
(fr)
|
2013-08-23 |
2015-02-25 |
MacroGenics, Inc. |
Bianticorps monovalents bi-spécifiques capables de se lier aux CD123 et CD3 et leurs utilisations
|
EP2840091A1
(fr)
|
2013-08-23 |
2015-02-25 |
MacroGenics, Inc. |
Diabody se liant specifiquement a l'antigene gpA33 et CD3 et procedes d'utilisation
|
US10407502B2
(en)
|
2014-01-15 |
2019-09-10 |
Kadmon Corporation, Llc |
Immunomodulatory agents
|
TWI681969B
(zh)
|
2014-01-23 |
2020-01-11 |
美商再生元醫藥公司 |
針對pd-1的人類抗體
|
TWI680138B
(zh)
|
2014-01-23 |
2019-12-21 |
美商再生元醫藥公司 |
抗pd-l1之人類抗體
|
TWI707872B
(zh)
|
2014-05-29 |
2020-10-21 |
美商宏觀基因股份有限公司 |
特異性結合多種癌症抗原的三特異性結合分子和其使用方法
|
JP6526189B2
(ja)
|
2014-07-03 |
2019-06-05 |
ベイジーン リミテッド |
抗pd−l1抗体並びにその治療及び診断のための使用
|
WO2016007235A1
(fr)
|
2014-07-11 |
2016-01-14 |
Genentech, Inc. |
Anticorps anti-pd-l1 et leurs utilisations
|
EP3171892B1
(fr)
|
2014-07-22 |
2021-11-24 |
Apollomics Inc. |
Anticorps anti-pd-1
|
WO2016022939A1
(fr)
|
2014-08-08 |
2016-02-11 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Services |
Anticorps monoclonaux humains spécifiques de 5t4 et leurs procédés d'utilisation
|
CA2959171C
(fr)
|
2014-09-05 |
2023-11-14 |
Janssen Pharmaceutica Nv |
Agents de liaison cd123 et leurs utilisations
|
CR20170109A
(es)
|
2014-09-26 |
2017-07-26 |
Macrogenics Inc |
Diacuerpos monovalentes biespecificos que son capaces de unir cd19 y cd3, y usos de los mismos
|
EP4245376A3
(fr)
|
2014-10-14 |
2023-12-13 |
Novartis AG |
Molécules d'anticorps de pd-l1 et leurs utilisations
|
WO2016073860A1
(fr)
|
2014-11-06 |
2016-05-12 |
Medimmune, Llc |
Molécules de liaison spécifique de la protéine a de staphylococcus et leurs utilisations
|
US10822414B2
(en)
|
2014-11-11 |
2020-11-03 |
Sutro Biopharma, Inc. |
Anti-PD-1 antibodies, compositions comprising anti-PD-1 antibodies and methods of using anti-PD-1 antibodies
|
JP2017536830A
(ja)
|
2014-11-26 |
2017-12-14 |
ゼンコー・インコーポレイテッドXencor、 Inc. |
Cd3及びcd38に結合するヘテロ二量体抗体
|
US10259887B2
(en)
|
2014-11-26 |
2019-04-16 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and tumor antigens
|
TWI595006B
(zh)
|
2014-12-09 |
2017-08-11 |
禮納特神經系統科學公司 |
抗pd-1抗體類和使用彼等之方法
|
US10239942B2
(en)
|
2014-12-22 |
2019-03-26 |
Pd-1 Acquisition Group, Llc |
Anti-PD-1 antibodies
|
GB201500319D0
(en)
|
2015-01-09 |
2015-02-25 |
Agency Science Tech & Res |
Anti-PD-L1 antibodies
|
JP2018503399A
(ja)
*
|
2015-01-14 |
2018-02-08 |
コンパス セラピューティクス リミテッド ライアビリティ カンパニー |
多特異性免疫調節抗原結合構築物
|
CN107921104A
(zh)
|
2015-02-22 |
2018-04-17 |
索伦托治疗有限公司 |
结合cd137的抗体疗法
|
US20160257761A1
(en)
|
2015-03-06 |
2016-09-08 |
Macrogenics, Inc. |
HER2/neu-Specific Antibodies and Methods of Using Same
|
CN107636014B
(zh)
*
|
2015-05-04 |
2021-12-07 |
皮里斯制药有限公司 |
抗癌融合多肽
|
AU2016262368B2
(en)
|
2015-05-08 |
2019-05-16 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and tumor antigens
|
TWI773646B
(zh)
*
|
2015-06-08 |
2022-08-11 |
美商宏觀基因股份有限公司 |
結合lag-3的分子和其使用方法
|
EP3313818B1
(fr)
|
2015-06-26 |
2023-11-08 |
Celgene Corporation |
Procédés pour le traitement du sarcome de kaposi ou le lymphome induit par le kshv à l'aide de composés immunomodulateurs et utilisations de biomarqueurs
|
US10513558B2
(en)
|
2015-07-13 |
2019-12-24 |
Cytomx Therapeutics, Inc. |
Anti-PD1 antibodies, activatable anti-PD1 antibodies, and methods of use thereof
|
IL297090A
(en)
|
2015-07-30 |
2022-12-01 |
Macrogenics Inc |
Molecules that bind pd-1 and methods of using them
|
CN108350072B
(zh)
|
2015-08-03 |
2022-05-24 |
诺华股份有限公司 |
治疗fgf21相关病症的方法
|
CN107921130A
(zh)
|
2015-08-17 |
2018-04-17 |
宏观基因有限公司 |
能够结合b7‑h3和cd3的双特异性单价双抗体及其用途
|
MA43186B1
(fr)
|
2015-11-03 |
2022-03-31 |
Janssen Biotech Inc |
Anticorps se liant spécifiquement à pd-1 et leurs utilisations
|
WO2017087547A1
(fr)
|
2015-11-17 |
2017-05-26 |
Oncomed Pharmaceuticals, Inc. |
Agents de liaison à pd-l1 et leurs utilisations
|
MX2018007423A
(es)
|
2015-12-17 |
2018-11-09 |
Novartis Ag |
Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas.
|
CA3006529A1
(fr)
|
2016-01-08 |
2017-07-13 |
F. Hoffmann-La Roche Ag |
Procedes permettant de traiter des cancers positifs a cea au moyen d'antagonistes de liaison a l'axe de pd-1 et d'anticorps bispecifiques anti-cea/anti-cd3
|
AU2017207742B2
(en)
|
2016-01-11 |
2022-03-17 |
Inhibrx Biosciences, Inc. |
Multivalent and multispecific 41BB-binding fusion proteins
|
WO2017142928A1
(fr)
|
2016-02-17 |
2017-08-24 |
Macrogenics, Inc. |
Molécules de liaison de ror1, et procédés d'utilisation de celles-ci
|
EP3471754A1
(fr)
|
2016-06-20 |
2019-04-24 |
Kymab Limited |
Anticorps anti-pd-l1
|
US9567399B1
(en)
|
2016-06-20 |
2017-02-14 |
Kymab Limited |
Antibodies and immunocytokines
|
CA3038020A1
(fr)
|
2016-09-23 |
2018-03-29 |
Merus N.V. |
Molecules de liaison bispecifique liant cd137
|
US11459394B2
(en)
|
2017-02-24 |
2022-10-04 |
Macrogenics, Inc. |
Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof
|
EA201892312A1
(ru)
|
2017-03-17 |
2019-04-30 |
Санофи |
Триспецифические и/или тривалентные связывающие белки
|
SG11202000198QA
(en)
|
2017-08-04 |
2020-02-27 |
Genmab As |
Binding agents binding to pd-l1 and cd137 and use thereof
|
WO2019072870A1
(fr)
|
2017-10-10 |
2019-04-18 |
Numab Innovation Ag |
Anticorps ciblant le cd137 et leurs méthodes d'utilisation
|
EP3694873A1
(fr)
|
2017-10-10 |
2020-08-19 |
Numab Therapeutics AG |
Anticorps multispécifiques
|
WO2019104716A1
(fr)
|
2017-12-01 |
2019-06-06 |
Adagene Inc. |
Méthodes d'utilisation du ligand cd137 comme biomarqueur pour le traitement avec un anticorps anti-cd137
|
MX2020009863A
(es)
|
2018-03-23 |
2021-01-08 |
Lilly Co Eli |
Anticuerpos anti-cd137 para combinacion con anticuerpos anti-pd-l1.
|